This alliance marks a shift in biopharma R&D, with the launch of the Biophysics Institute for Biomedical Research (IBRB), offering top-tier scientific instrumentation and collaborative research support.
Bruker’s minority stake in NovAliX, coupled with the collaboration’s focus on advanced analytical tools and biophysical expertise, positions the two companies to reshape the research landscape, particularly in biopharma, where increasing development costs and complexity demand new approaches to drug discovery.
At the core of this partnership is a commitment to advancing structural biology, biophysics, and pharmacology capabilities, all critical for accelerating drug development. Bruker’s strategic investment allows NovAliX to expand its suite of services for early-stage research, enhancing the CRO’s ability to deliver targeted, data-driven insights at each development stage. For Bruker, the collaboration offers a unique pathway to leverage its high-end analytical solutions, effectively embedding its instruments into the early discovery process.
A pivotal component of the partnership is the establishment of the Biophysics Institute for Biomedical Research (IBRB). This new institution, supported by NovAliX, Bruker, and the Max Planck Institute, will serve as a hub for scientific exchange and drug discovery. Designed to house the most advanced biophysics equipment, the IBRB will provide resident and visiting scientists from the biopharma industry access to tools and expertise that accelerate therapeutic development. This collaborative setting not only enables rapid data generation but also fosters real-time problem-solving, which can significantly shorten research timelines.
“The IBRB represents a significant leap in fostering scientific innovation,” said Denis Zeyer, CEO of NovAliX.
“By combining resources and providing access to shared knowledge and instrumentation, we’re able to support early discovery and maturation of therapeutic innovations. The structure of the IBRB allows stakeholders to collaborate in a way that was previously unavailable to early-stage researchers.”
This unique model, uniting a CRO, an academic powerhouse, and an instrument leader, is designed to maximize research efficiency and therapeutic discovery success. By enabling a more streamlined approach, NovAliX and Bruker anticipate that IBRB will be a game-changer for CRO services, enhancing support for biopharmaceutical development through expanded biophysical and structural biology expertise.
Falko Busse, president of Bruker BioSpin, emphasized the strategic nature of the partnership. He said: “NovAliX’s position as a leading drug discovery CRO with a strong biophysical and technological focus made them an ideal partner for Bruker. Together with the IBRB, we are breaking new ground in therapeutic discovery, ensuring that the latest technologies and methods are readily available to accelerate R&D for the benefit of patients.”
This partnership also enables NovAliX to strengthen its footprint in the U.S., where it will establish new scientific and technology platforms that broaden service capabilities. By combining NovAliX’s experience with Bruker’s technological assets, both companies aim to streamline early-stage research, reduce costs, and enhance the success of drug development projects.
This collaboration between a high-tech CRO and an instrumentation leader signals a new era in biopharma, one where CROs, academic institutions, and technology providers align to support the next wave of therapeutic innovation. As the industry seeks more efficient and impactful pathways to drug development, alliances like that of NovAliX and Bruker represent a significant step forward.